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Abstract
Information on the relatedness of isolates causing repeated meticillin-resistant Staphylococcus aureus (MRSA) bacteraemia is limited. An
observational study of 177 patients with MRSA bacteraemia, admitted to the emergency department of National Taiwan University
Hospital, was conducted from January 2001 to June 2006. Among these patients, 28 had a previous episode of MRSA bacteraemia and
59 died during the index episode of bacteraemia. Until December 2007, among the 118 patients who survived the index episode (101
without previous bacteraemia and 17 with previous bacteraemia), 24 (20.3%) had repeated MRSA bacteraemia. The duration from dis-
continuation of antimicrobial therapy to repeat episodes was in the range 35–854 days (median 86 days). Eight patients (33.3%) died as
a result of the second bacteraemic episode. Clinical characteristics associated with repeated bacteraemia included the diagnosis of infec-
tive endocarditis and active malignancy. Pulsed-field gel electrophoresis and multilocus sequence typing analysis were performed for 32
pairs of available isolates recovered from patients with repeated bacteraemia and revealed that 29 of them (90.6%) were genetically clo-
sely-related strains. The majority of patients with repeated MRSA bacteraemia had recurrent infections and a high mortality rate.
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Introduction
Because of advances in patient care and the pathogen’s ability
to adapt to a changing environment, the incidence of Staphy-
lococcus aureus infection has gradually increased. The emer-
gence of meticillin-resistant S. aureus (MRSA) is a growing
clinical challenge in hospital-associated settings and, more
recently, in community settings in the USA and globally [1].
In Taiwan, the prevalence of MRSA infection is approximately
60% of nosocomial S. aureus infections [2] and MRSA is also
an emerging community-onset pathogen [3].
The impact of the increasing frequency of MRSA bactera-
emia is magnified by the poor outcome associated with this
serious infection. A growing body of evidence now supports a
worse overall outcome for patients with MRSA bacteraemia
compared to that for similar patients with meticillin-susceptible
S. aureus infection [4]. These findings highlight the importance
of expedient and aggressive management of MRSA bactera-
emia. Repeated S. aureus bacteraemia is not uncommon, and
the risk is higher for MRSA [5–8], although detailed molecular
epidemiology of this clinical entity is limited. A previous report
indicated that cases of recurrent S. aureus bacteraemia were
associated with an indwelling foreign body, with receiving
vancomycin therapy, or with haemodialysis dependency [5].
An observational study of 177 patients with MRSA bactera-
emia admitted to the emergency department (ED) of National
Taiwan University Hospital was conducted from January 2001
to June 2006 [9]. Twenty-eight patients had a history of MRSA
bacteraemia prior to the ED visit (inclusion in the study).
Among the 118 patients who survived during the hospital stay
after inclusion in the study, 24 (20.3%) had repeated MRSA
bacteraemia until December 2007. This study investigated the
clinical features of patients with repeated MRSA bacteraemia
and evaluated the strain-relatedness of MRSA isolates causing
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repeated bacteraemia using pulsed-field gel electrophoresis
(PFGE) and multilocus sequence typing (MLST) analysis.
Materials and Methods
Hospital setting and patient selection
National Taiwan University Hospital (NTUH) is a 2200 bed,
academically affiliated medical centre providing both primary
and tertiary care in northern Taiwan. This study included all
patients aged >16 years with positive S. aureus blood cultures
within 48 h of arrival at the ED from January 2001 to June
2006. Patients who had been hospitalized for >48 h or who
were discharged from any hospital within 48 h were consid-
ered to have hospital-onset bacteraemia [10]. Healthcare-
associated bacteraemia included bacteraemia related to
receiving haemodialysis, chemotherapy or parenteral nutri-
tion on an outpatient basis, nursing home stay, recent sur-
gery or prior hospitalization within 1 year [10]. Bacteraemia
in patients without any of the risk factors mentioned above
was defined as community-onset bacteraemia.
During the study period, the annual number of ED patient
visits was approximately 84 000, and the annual number of
positive blood cultures was approximately 1400 (positive
rate of blood culture was approximately 17.6%). Among the
bacterial isolates from positive blood cultures, 25.2% were
Gram-positive bacteria, and S. aureus comprised approxi-
mately 9.4 % of all isolates. The prevalence of community-
onset MRSA bacteraemia is increasing (from 0.009 per 1000
ED visits in 2001 to 0.091 in 2006) [11].
Data collection
The clinical courses and primary sites of bacteraemia were
evaluated based on information supplied by primary care
physicians and medical records. Data recorded for each
patient comprised: age; sex; underlying illness; severity of ill-
ness classified by McCabe–Jackson criteria [12]; severity of
bacteraemia assessed by the Pittsburg bacteraemia score
[13]; installation of a foreign body, including prosthetic
joint, pacemaker or intravenous/Foley catheter; debridement,
including catheter/foreign body removal or surgical debride-
ment of infected tissue; and metastatic infection, which
included documented MRSA infection remote from the origi-
nal site. Inactive malignancy was not included as an underly-
ing illness. For patients who were not admitted to NTUH,
telephone contact was made to collect the required informa-
tion (four patients were admitted to other hospitals for dif-
ferent reasons after the ED admission). A glycopeptide is the
suggested treatment for MRSA infection at our institute, and
linezolid is under the control of infectious disease physicians.
Early initiation of empirical glycopeptide treatment is not
encouraged at our institute [14]. Empirical antimicrobial
therapy was defined as adequate when patients received anti-
microbial agents active in vitro as determined by routine disk
susceptibility testing before the notification of MRSA.
Microbiology and antimicrobial susceptibility
Blood culture specimens were inoculated into BACTEC or
BACTEC PLUS culture bottles using the BACTEC 9000 sys-
tem (Becton Dickinson, Sparks, MA, USA). Susceptibilities to
antimicrobial agents were determined by the standard disk
diffusion method [15]. Subsequent to 2006, a 30-lg cefoxitin
disk (BBL Microbiology Systems, Cockeysville, MD, USA) has
been applied to detect MRSA [16]. Clinical isolates of MRSA
TABLE 1. Comparison of 28 patients with meticillin-resis-
tant Staphylococcus aureus (MRSA) bacteraemia prior to vis-
its to the emergency department and 149 patients without
prior MRSA bacteraemia
Variables
Without
prior MRSA
bacteraemia
(n = 149)
With prior
MRSA
bacteraemia
(n = 28)
Age 66.3 ± 16.0 63.0 ± 17.1
Sex (male/female) 86/63 19/9
Source of patients
Community 21 (14.1) 0 (0)
Healthcare 110 (73.8) 24 (85.7)
Nosocomial 18 (12.1) 4 (14.3)
McCabe classification
Rapidly fatal disease 12 (8.0) 1 (3.6)
Ultimately fatal disease 73 (49.0) 20 (71.4)
Nonfatal disease 64 (43.0) 7 (25.0)
Foreign body 66 (44.3) 12 (42.9)
Debridement 58 (38.9) 11 (39.3)
Pittsburg bacteraemia Score 3.5 ± 3.2 3.9 ± 3.6
Adequate empirical
antimicrobial therapy
18 (12.1) 11 (39.3)*
Underlying illness
Diabetes mellitus 56 (37.6) 9 (32.1)
End-stage renal disease 33 (22.1) 11 (39.3)
Heart disease 31 (20.8) 7 (25.0)
Stroke 36 (24.2) 5 (17.9)
Active malignancy 32 (21.5) 3 (10.7)
Liver cirrhosis 9 (6.0) 4 (14.3)
Intravenous drug user 4 (2.7) 0 (0)
Predisposing factors
Arterio-venous fistula/graft 21 (14.1) 8 (28.6)
Catheter use 47 (31.5) 8 (28.6)
Double lumen catheter 16 (10.7) 5 (17.9)
Port-A catheter 16 (10.7) 1 (3.6)
Perm-cath 11 (7.4) 1 (3.6)
Central venous catheter 5 (3.4) 1 (3.6)
Foley 17 (11.4) 1 (3.6)
Type of infection
Catheter related 34 (22.8) 6 (21.4)
Soft tissue infection 31 (20.8) 6 (21.4)
Primary bacteraemia 20 (13.4) 7 (25.0)
Orthopedic infection 15 (10.1) 1 (3.6)
Infective endocarditis 9 (6.0) 3 (10.7)
Respiratory tract infection 22 (14.8) 2 (7.1)
Endovascular infection
other than infective endocarditis
6 (4.0) 3 (10.7)
Urinary tract infection 10 (6.7) 0 (0)
Biliary tract infection 2 (1.3) 0 (0)
Metastatic infection 17 (11.4) 6 (21.4)
In-hospital mortality 48 (32.2) 11 (39.3)
*p <0.05
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were collected and stored at )70C in trypticase soy broth
(Difco Laboratories, Detroit, MI, USA) supplemented with
15% glycerol.
Definition of clinical status
Infective endocarditis (IE) was defined according to the mod-
ified Duke criteria [17]; catheter-related bacteraemia was
defined as a positive semiquantitative tip culture (‡15 CFU)
and/or high clinical suspicion; pneumonia was defined as a
MRSA-positive culture from purulent sputum samples and
the presence of newly-developed lung infiltrates; urinary
tract infection was defined as a positive urine culture and
pyuria; orthopaedic infections included osteomyelitis docu-
mented by pathology or imaging study with compatible clini-
cal findings, prosthetic joint infection or septic arthritis and/
or positive microbiological results obtained according to cur-
rent suggestions [18]; and soft tissue infection was defined as
clinical soft tissue inflammation plus bacteraemia. If no pri-
mary focus could be identified, the bacteraemia was classified
as primary. Routine decolonization of MRSA was not per-
formed in our hospital. Repeated bacteraemia within 28 days
of discontinuing antimicrobial agent was considered as
incomplete treatment.
PFGE and MLST
PFGE was performed on available repeated isolates from
MRSA bacteraemia. The details of the method used to per-
form PFGE were described in our previous study [19]. For
restriction endonuclease digestion of the DNA plug, SmaI
(New England Biolabs, Beverly, MA, USA) was used for
MRSA isolates. Other procedures were the same as those
described in our previous study [19]. The PFGE results were
analysed with Gelcompar for Windows, Version 3.1 (Applied
Math, Kortrijk, Belgium). Those differing by 2three bands
were considered to be closely-related strains [20]. More-
over, MLST was performed on these isolates [19], but
isolates with same MLST have not to be considered closely-
related.
Statistical analysis
The mean and standard deviation were calculated for
continuous variables. Percentage was used for categorical
variables. Student’s t-test was used for comparison of
continuous variables. Categorical variables were analysed by
chi squared or Fisher’s exact test. An univariate analysis for
risk factors of repeated bacteraemia was performed among
patients surviving the index hospitalization. Patients with a
history of MRSA bacteraemia prior to index hospitalization
were excluded. Factors associated with repeated bactera-
emia on univariate analysis (p <0.1) were further evaluated
with multivariate logistic regression with forward selection.
ORs and the corresponding 95% CIs were calculated. Data
were collected in a Microsoft Excel database (Microsoft
Excel 2001; Microsoft Corp., Seattle, WA, USA) and analy-
sed with SPSS software for Windows release 10.0 (SPSS Inc.,
Chicago, IL, USA).
Patients visited NTUH ED with MRSA bacteraemia 
from January 2001 to June 2006 (n = 177) 
Without prior MRSA bacteraemia (n = 149) 
101 patients survived (67.8%) 
With prior MRSA bacteraemia (n = 28) 
17 patients survived (60.7%) 
82 patients had 
no repeated 
MRSA bacteraemia 
until December 
2007 (81.2%)
12 patients had 
no repeated 
MRSA bacteraemia 
until Decemeber 
2007 (70.6%)
19 patients had 
repeated MRSA 
bacteraemia until 
December 2007 
(18.8%)
5 patients had 
repeated MRSA 
bacteraemia until 
Decemeber
2007 (29.4%)
FIG. 1. The distribution of 177 patients
presented to National Taiwan University
Hospital emergency department (NTUHED)
with methicillan-resistant Staphylococcus
aureus (MRSA) bacteraemia from January
2001 to June 2006. Until December 2007,
patients had reported MRSA bacteraemia.
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Results
From January 2000 to June 2006, a total of 177 patients with
MRSA bacteraemia were identified, of whom patients with
healthcare-associated MRSA bacteraemia comprised 75.7%.
Among the 177 patients, 59 (33.3%) patients died during the
index hospitalization. Twenty-eight of these patients had pre-
vious episodes of MRSA bacteraemia before inclusion in the
study and 11 (39.3%) of them died. The comparison
between patients with and those without prior MRSA bac-
teraemia showed no obvious differences, except that
patients in the group with prior MRSA bacteraemia received
a higher percentage of adequate empirical antimicrobial ther-
apy (Table 1). Among the remaining 118 patients, 24 devel-
oped repeated MRSA bacteraemia after inclusion in the
study (Fig. 1).
Patients with repeated bacteraemia
The comparisons of clinical characteristics of the 82 patients
with single episode of MRSA bacteraemia and the 24 patients
with repeated bacteraemia after the index hospitalizations
are summarized in Table 2. Twelve patients with a history of
MRSA bacteraemia, but with no repeated bacteraemia after
inclusion, were excluded (Fig. 1). The mean age of the 24
patients with repeated MRSA bacteraemia was 60 years and
14 (58.3%) of them were men. Healthcare-associated bacter-
aemia was the most common (91.7%) form and no commu-
nity-onset bacteraemia was identified in this group. Five of
them had a history of prior MRSA bacteraemia (two had
end-stage renal disease, two had active malignancy, and one
was an intravenous drug user). Forty-six per cent of patients
had a foreign body in place at the time of bacteraemia onset.
End-stage renal disease was the most common underlying
disease, followed by diabetes mellitus, heart disease and
TABLE 2. Comparison of 24 patients with repeated meticillin-resistant Staphylococcus aureus (MRSA) bacteraemia after visits
to the emergency department and 82 patients without repeated MRSA bacteraemia
Variables
Nonrepeated
bacteraemia (n = 82)
Repeated
bacteraemia (n = 24)
Odds
ratio 95% CI p value
Age 64.3 ± 16.6 60.0 ± 17.1 0.99 0.96–1.01 0.276
Sex (male/female) 47/35 14/10 1.04 0.41–2.62 0.929
Source of patients
Community 16 (19.5) 0 (0) – – –
Healthcare 59 (72.0) 22 (91.7) 4.29 0.93–19.72 0.061
Nosocomial 7 (8.5) 2 (8.3) – – –
McCabe classification
Rapidly fatal disease 1 (1.2) 1 (4.2) – – –
Ultimately fatal disease 33 (40.2) 18 (75.0) 4.45 1.60–12.40 0.004
Nonfatal disease 48 (58.5) 5 (20.8) – – –
Foreign body 32 (39.0) 11 (45.8) 1.85 0.74–4.62 0.190
Debridement 38 (46.3) 12 (50.0) 1.16 0.47–2.88 0.752
Pittsburg Bacteraemia Score 2.3 ± 2.1 2.8 ± 2.1 1.09 0.89–1.34 0.388
Adequate empirical antimicrobial
therapy
7 (8.5) 8 (33.3) 5.36 1.70–16.90 0.004
Duration of treatment 30.6 ± 29.8 31.3 ± 21.3 1.00 0.98–1.02 0.919
Underlying illness
Diabetes mellitus 28 (34.1) 8 (33.3) 0.96 0.37–2.53 0.941
End-stage renal disease 17 (20.7) 11 (45.8) 3.24 1.23–8.49 0.017
Heart disease 13 (15.9) 7 (29.2) 2.19 0.76–6.32 0.149
Stroke 20 (24.4) 3 (12.5) 0.44 0.12–1.64 0.223
Active malignancy 10 (12.2) 7 (29.2) 2.96 0.99–8.92 0.053
Liver cirrhosis 5 (6.1) 2 (8.3) 2.96 0.25–7.72 0.699
Intravenous drug user 2 (2.4) 2 (8.3) 3.64 0.48–27.30 0.209
Predisposing factors
Arterio-venous fistula/graft 12 (14.6) 8 (33.3) 2.92 1.02–8.31 0.045
Catheter use 22 (26.8) 10 (41.7) 1.95 0.76–5.02 0.168
Double lumen catheter 8 (9.8) 5 (20.8) 2.43 0.71–8.29 0.155
Port-A catheter 7 (8.5) 2 (8.3) 0.97 0.19–5.03 0.975
Perm-cath 4 (4.9) 3 (12.5) 2.79 0.58–13.42 0.202
Central venous catheter 3 (3.7) 0 (0) – – –
Foley 8 (9.8) 0 (0) – – –
Type of infection
Catheter related 17 (20.7) 8 (33.3) 1.91 0.70–5.21 0.205
Soft tissue infection 20 (24.4) 4 (16.7) 0.62 0.19–2.03 0.430
Primary bacteraemia 10 (12.2) 3 (12.5) 1.03 0.26–4.08 0.968
Orthopedic infection 14 (17.1) 1 (4.2) 0.21 0.03–1.70 0.143
Infective endocarditis 1 (1.2) 5 (20.8) 21.32 2.35–193.22 0.007
Respiratory tract infection 7 (8.5) 2 (8.3) 0.97 0.19–5.03 0.975
Endovascular infection other
than infective endocarditis
4 (4.9) 0 (0) – – –
Urinary tract infection 7 (8.5) 1 (4.2) 0.07 0.01–0.68 0.021
Biliary tract infection 2 (2.4) 0 (0) – – –
Metastatic infection 6 (7.3) 4 (16.7) 2.53 0.65–9.85 0.180
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stroke. Catheter-related bacteraemia was the most common
type of infection (33.3%), followed by infective endocarditis
(20.8%), soft tissue infection (16.7%) and primary bactera-
emia (12.5%). The duration from discontinuation of therapy
to repeated episodes was in the range 35–854 days (median
86 days). Eight patients (33.3%) died during the second epi-
sode of MRSA bacteraemia.
Comparison of patients with single and repeated
bacteraemia
Patients with repeated MRSA bacteraemia were more likely
to have ultimately fatal disease, received adequate empirical
antimicrobial therapy, end-stage renal disease, active malig-
nancy, arterio-venous fistula/graft and infective endocarditis
(Table 2). Patients with urinary tract infection had less
repeated bacteraemia. The duration of treatment and sever-
ity of bacteraemia were not significant factors for repeated
bacteraemia. Multivariate analysis showed a diagnosis of infec-
tive endocarditis (OR 26.09, 95% CI 2.51–270.77, p 0.006)
and active malignancy (OR 5.10, 95% CI 1.47–17.68, p 0.01)
were significant predictors of recurrent MRSA bacteraemia.
End-stage renal disease (OD 3.00, 95% CI 0.90–9.99, p 0.07)
was of borderline significance.
PFGE of isolates of repeated MRSA bacteraemia
Among the 24 patients with repeated bacteraemia after
index ED visits, 15 patients had available isolates (15 pairs
of isolates) for PFGE analysis. Among the 15 pairs of
repeated isolates, 13 (86.7%) were closely-related (Fig. 2).
ST239 was the most common genotype (20 isolates), fol-
lowed by ST59 (five isolates) and ST149 (three isolates).
Among the 28 patients with prior MRSA bacteraemia
before index ED visit, 17 patients had available previous
MRSA isolates (17 pairs of isolates) and 16 (94.1%) of them
were closely-related (Fig. 3). ST239 was again the most
common genotype (17 isolates), followed by ST149 (six iso-
lates), ST59 (four isolates) and ST573 (two isolates). In
total, 29 (90.6%) of the 32 pairs of MRSA isolates causing
repeated bacteraemia were identified as genetically closely-
related strains.
Discussion
Recurrence is an important concern in patients with
S. aureus bacteraemia, especially for MRSA. Fowler et al. [5]
reported that 82.1% of recurrent S. aureus bacteraemia cases
were the result of PFGE confirmed relapse. In the present
study, similar PFGE patterns to previous isolates were found
in 90.6% of the isolates of patients with repeated MRSA
bacteraemia. These findings might imply incomplete treat-
ment for occult focus or persistent carriage of the same
strain.
Fowler et al. [5] found that 86% of patients with recurrent
S. aureus bacteraemia developed a second episode within
90 days of their initial infection. However, in the present
study, the duration from discontinuation of therapy to recur-
rence was in the range 35–854 days (median 86 days) and
only half of the patients developed the second episode of
MRSA bacteraemia within 90 days. This variation in second
episode timing is so large that clinicians should be alert to
the possibility of repeated MRSA bacteraemia even months
after the initial episode.
Previous studies showed infective endocarditis was a risk
factor for recurrence of S. aureus bacteraemia [21] and diffi-
cult to treat [22]. The present study confirmed that IE was
significantly associated with recurrent MRSA bacteraemia. In
our hospital, transoesophageal echocardiography was not
routinely performed for patients with MRSA bacteraemia.
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FIG. 2. Pulsed-field gel electrophoresis patterns of isolates recov-
ered from 15 patients (patients A to O) with repeated meticillin-
resistant Staphylococcus aureus bacteraemia after visits to the
emergency department (1, original isolate; 2, repeat isolates).
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Thus, an under-diagnosis of IE [23] might explain why only
five patients with repeated MRSA bacteraemia had an IE
diagnosis in the present study. The present study indicates
that the current recommendation to perform transoesopha-
geal echocardiography for all patients with MRSA bactera-
emia should be applied more strictly [24]. Active malignancy
was significantly associated with repeated MRSA bacteraemia
in this study. Among the seven patients with both malignancy
and repeated bacteraemia, four had intravascular catheters.
Our findings reveal that the risk factors for repeated MRSA
bacteraemia included the use of intravascular catheters, an
immunocompromised condition, and frequent hospital visits
and interventions [25]. Previous studies also found that end-
stage renal disease was significantly associated with increased
MRSA bacteraemia [26] and repeated bacteraemia [5]. The
causes of MRSA bacteraemia in these patients were similar
to those found in patients with malignancy, as well as those
related to the existence of a foreign body and repeated med-
ical interventions.
A study by Huang et al. [6] suggested that most repeated
MRSA infections were caused by same strain, and that a sin-
gle successful decolonization may prevent the majority of
later MRSA infection. The present study provided similar
findings in that most isolates from patients with repeated
MRSA bacteraemia showed close genetic relatedness. How-
ever, the effect of decolonization remains controversial,
most likely as a result of the extensive nature of the sites
that MRSA could colonize and the limited methods available
to eradicate MRSA [27]. Moreover, Pena et al. [28] demon-
strated that, in patients on haemodialysis receiving mupirocin
for decolonization of MRSA nasal carriage, 43.5% had nasal
recurrence, and 70% of them were considered as relapsed
according to PFGE results. Regular nasal swabs for MRSA
were not routinely performed during the present study, and
related data are required in patients with MRSA bacteraemia
to determine whether a more direct relationship exists
between colonization and invasive infections.
In the present study, although patients with repeated bac-
teraemia were more likely to receive adequate empirical anti-
microbial treatment, they still showed higher mortality and
recurrence. The explanation of higher possibility of adequate
empirical therapy in patients with repeated bacteraemia cen-
tres on patients’ underlying illness, especially end-stage renal
disease and active malignancy, which might encourage aggres-
sive empirical therapy. The effectiveness of empirical glycopep-
tides on patient outcome has been controversial [14,29,30]. In
our previous study [9], we showed that the severity of under-
lying illness, and the severity of bacteraemia and persistent
bacteraemia, were correlated with mortality, and not with
empirical therapy. On the other hand, we maintain that empir-
ical therapy is not a major factor for recurrence. The com-
pleteness of adequate target therapy is more important.
However, although prolonged treatment has been suggested
for MRSA bacteraemia [31], the duration of treatment is not a
significant factor for recurrence in the present study, in accor-
dance with a previous report by Kreisel et al. [8].
The present study has several limitations. First, the possi-
bility of incomplete treatment or any occult focus could not
be excluded despite the fact that half of our patients had
repeated infection at least 3 months later, which is longer
than the suggested observation period for S. aureus bactera-
emia. Second, most of our cases were healthcare-associated
MRSA strains. The genotype analyses showed that the most
common isolate was ST239, which was the most prevalent
healthcare-associated strain in Taiwan [19]. However, there
were still a few ST59 strains (SCCmec IV or V) among
patients with repeated bacteraemia, which were common
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FIG. 3. Pulsed-field gel electrophoresis patterns of isolates recov-
ered from 17 patients (patients a to q) with repeated meticillin-resis-
tant Staphylococcus aureus (MRSA) bacteraemia who had prior
nosocomial MRSA bacteraemia isolates prior to visits to the emer-
gency department (ED) and isolates after ED visits (1, prior isolate;
2, isolate obtained in this study).
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community-onset MRSA strains [11], although none of the
patients were considered as having true community-onset
MRSA bacteraemia. This might only reflect that ST59 is
replacing ST239 as healthcare-related strain. Because of geo-
graphic differences, the results obtained in the present stusy
can not be generalized to other settings. Third, because we
did not perform environmental cultures, the contribution of
a patient’s immediate surroundings to maintaining carriage
with the same strain could not be assessed [6].
In conclusion, repeated MRSA bacteraemia is common
and carries a high mortality rate. Most cases were recurrent
infections caused by the same strains. Clinical characteristics
associated with repeated bacteraemia included a diagnosis of
infective endocarditis and active malignancy.
Transparency Declaration
The authors declare no conflict of interests.
References
1. Boucher HW, Corey GR. Epidemiology of methicillin-resistant Staphy-
lococcus aureus. Clin Infect Dis 2008; 46 (suppl 5): 344S–349S.
2. Hsueh PR, Chen ML, Sun CC et al. Antimicrobial drug resistance in
pathogens causing nosocomial infections at a university hospital in
Taiwan, 1981–1999. Emerg Infect Dis 2002; 8: 63–68.
3. Chen CJ, Huang YC. Community-acquired methicillin-resistant Staphy-
lococcus aureus in Taiwan. J Microbiol Immunol Infect 2005; 38: 376–382.
4. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer
AW, Carmeli Y. Comparison of mortality associated with methicillin-
resistant and methicillin-susceptible Staphylococcus aureus bacteremia:
a meta-analysis. Clin Infect Dis 2003; 36: 53–59.
5. Fowler VG Jr, Kong LK, Corey GR et al. Recurrent Staphylococcus
aureus bacteremia: pulsed-field gel electrophoresis findings in 29
patients. J Infect Dis 1999; 179: 1157–1161.
6. Huang SS, Diekema DJ, Warren DK et al. Strain-relatedness of methi-
cillin-resistant Staphylococcus aureus isolates recovered from patients
with repeated infection. Clin Infect Dis 2008; 46: 1241–1247.
7. Hartstein AI, Mulligan ME, Morthland VH, Kwok RY. Recurrent
Staphylococcus aureus bacteremia. J Clin Microbiol 1992; 30: 670–674.
8. Kreisel K, Boyd K, Langenberg P, Roghmann MC. Risk factors for
recurrence in patients with Staphylococcus aureus infections compli-
cated by bacteremia. Diagn Microbiol Infect Dis 2006; 55: 179–184.
9. Liao CH, Chen SY, Huang YT, Hsueh PR. Outcome of patients with
meticillin-resistant Staphylococcus aureus bacteraemia at an emergency
department of a medical centre in Taiwan. Int J Antimicrob Agents
2008; 32: 326–332.
10. Liao CH, Chen SY, Chang SC, Hsueh PR, Hung CC, Chen YC. Char-
acteristics of community-acquired and health care-associated Staphylo-
coccus aureus bacteremia in patients treated at the emergency
department of a teaching hospital. Diagn Microbiol Infect Dis 2005; 53:
85–92.
11. Wang JL, Chen SY, Wang JT et al. Comparison of both clinical
features and mortality risk associated with bacteremia due to
community-acquired methicillin-resistant Staphylococcus aureus and
methicillin-susceptible S. aureus. Clin Infect Dis 2008; 46: 799–806.
12. McCabe WR, Jackson GG. Gram-negative bacteremia. Arch Intern
Med 1962; 110: 847–864.
13. Chow JW, Fine MJ, Shlaes DM et al. Enterobacter bacteremia: clinical
features and emergence of antibiotic resistance during therapy. Ann
Intern Med 1991; 115: 585–590.
14. Fang CT, Shau WY, Hsueh PR et al. Early empirical glycopeptide ther-
apy for patients with methicillin-resistant Staphylococcus aureus bac-
teraemia: impact on the outcome. J Antimicrob Chemother 2006; 57:
511–519.
15. National Committee for Clinical Laboratory Standards. Performance
standards for antimicrobial disk susceptibility tests, 8th edn. Approved
standard. M2-A8. Wayne, PA: NCCLS, 2003.
16. Clinical and Laboratory Standards Institute. Performance standards for
antimicrobial susceptibility testing. Sixteenth informational supplement.
M100-S17. Wayne, PA: CLSI, 2007.
17. Li JS, Sexton DJ, Mick N et al. Proposed modifications to the Duke
criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000;
30: 633–638.
18. Wilson ML, Winn W. Laboratory diagnosis of bone, joint, soft-tissue,
and skin infections. Clin Infect Dis 2008; 46: 453–457.
19. Huang YH, Tseng SP, Hu JM, Tsai JC, Hsueh PR, Teng LJ. Clonal
spread of SCCmec type IV methicillin-resistant Staphylococcus aureus
between community and hospital. Clin Microbiol Infect 2007; 13: 717–
724.
20. Tenover FC, Arbeit RD, Goering RV et al. Interpreting chromosomal
DNA restriction patterns produced by pulsed-field gel electrophoresis
criteria for bacterial strain typing. J Clin Microbiol 1995; 33: 2233–2239.
21. Chang FY, Peacock JE Jr, Musher DM et al. Staphylococcus aureus bac-
teremia: recurrence and the impact of antibiotic treatment in a pro-
spective multicenter study. Medicine (Baltimore) 2003; 82: 333–339.
22. Hsu RB, Chu SH. Impact of methicillin resistance on clinical features
and outcomes of infective endocarditis due to Staphylococcus aureus.
Am J Med Sci 2004; 328: 150–155.
23. Bayer AS. Infective endocarditis. Clin Infect Dis 1993; 17: 313–320.
24. Baddour LM, Wilson WR, Bayer AS et al. Infective endocarditis: diag-
nosis, antimicrobial therapy, and management of complications: a
statement for healthcare professionals from the Committee on Rheu-
matic Fever, Endocarditis, and Kawasaki Disease, Council on Cardio-
vascular Disease in the Young, and the Councils on Clinical
Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia,
American Heart Association: endorsed by the Infectious Diseases
Society of America. Circulation 2005; 111: e394–e434.
25. Gopal AK, Fowler VG Jr, Shah M et al. Prospective analysis of Staphy-
lococcus aureus bacteremia in nonneutropenic adults with malignancy.
J Clin Oncol 2000; 18: 1105–1115.
26. Centers for Disease Control and Prevention (CDC). Invasive methi-
cillin-resistant Staphylococcus aureus infections among dialysis
patients – United States, 2005. MMWR Morb Mortal Wkly Rep 2007;
56: 197–199.
27. Wertheim HF, Melles DC, Vos MC et al. The role of nasal carriage in
Staphylococcus aureus infections. Lancet Infect Dis 2005; 5: 751–762.
28. Pen˜a C, Ferna´ndez-Sabe N, Domı´nguez MA et al. Staphylococcus
aureus nasal carriage in patients on haemodialysis: role of cutaneous
colonization. J Hosp Infect 2004; 58: 20–27.
29. Schramm GE, Johnson JA, Doherty JA, Micek ST, Kollef MH.
Methicillin-resistant Staphylococcus aureus sterile-site infection: the
importance of appropriate initial antimicrobial treatment. Crit Care
Med 2006; 34: 2069–2074.
30. Go´mez J, Garcı´a-Va´zquez E, Ban˜os R et al. Predictors of mortality
in patients with methicillin-resistant Staphylococcus aureus (MRSA)
bacteraemia: the role of empiric antibiotic therapy. Eur J Clin Microbiol
Infect Dis 2007; 26: 239–245.
31. Cosgrove SE, Fowler VG Jr. Management of methicillin-resistant
Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46: S386–S393.
CMI Liao et al. Strain relatedness of repeated MRSA bacteraemia 469
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 463–469
